CLAIMS

What is claimed is:

1. Use of riluzole, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating amyotrophic lateral sclerosis (ALS) ~~disease~~ in a patient in need thereof,

wherein the medicament comprises about 50-70 weight% riluzole, or a pharmaceutically acceptable salt thereof, about 10-30 weight% fish gelatin, about 10-20 weight% of a filler, and 0.1-5.0 weight% of a flavorant, and

wherein the medicament is in the form of an oral solid molded fast-dispersing dosage form in order to provide an AUC_{0-t} of from about 80-125% of about 740000 hr*pg/mL~~, wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 50 to 90% of the dosage of riluzole in a conventional tablet in order to provide an AUC_{0-t} of about 740000 hr*pg/mL~~.

~~2. The use of claim 1 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 70 to 85% of the dosage of riluzole in a conventional tablet in order to provide an AUC_{0-t} of about 740000 hr*pg/mL~~

~~3. The use of claim 2 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 80% of the dosage of riluzole in a conventional tablet in order to provide an AUC_{0-t} of about 740000 hr*pg/mL.~~

2~~4~~. The use of claim 1, wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 40 mg.

3. The use of claim 1, wherein the filler is mannitol.

~~5. The use of claim 1 wherein the disease is ALS.~~

4~~6~~. A pharmaceutical composition for use in the treatment of amyotrophic lateral sclerosis (ALS),

wherein the pharmaceutical composition comprises~~ing a therapeutically effective amount of~~ about 50-70 weight% riluzole, or a pharmaceutically acceptable salt thereof, about 10-30 weight% fish gelatin, about 10-20 weight% of a filler, and 0.1-5.0 weight% of a flavorant, and

wherein the pharmaceutical composition is in the form of an oral solid molded fast-dispersing dosage form in order to provide an AUC_{0-t} of from about 80-125% of about 740000 hr*pg/mL~~, wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 50 to 90%, more preferably 70 to 85% and most preferably about 80% o of the dosage of riluzole in a conventional tablet in order to provide an AUC_{0-t} of about 740000 hr*pg/mL~~.

~~7. The pharmaceutical composition of claim 6 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 70 to 85% of the dosage of riluzole in a conventional tablet in order to provide an AUC_{0-t} of about 740000 hr*pg/mL.~~

~~8. The pharmaceutical composition of claim 6 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 80% of the dosage of riluzole in a conventional tablet in order to provide an AUC_{0-t} of about 740000 hr*pg/mL.~~

5~~9~~. The pharmaceutical composition of claim 4~~6~~, wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 40 mg.

~~10. The pharmaceutical composition of claim 6 comprising from about 50-70 wt% riluzole, about 10-30 wt% fish gelatin, about 10-20 wt% of a filler, and 0.1-5.0 wt% of a flavorant.~~

6~~11~~. The pharmaceutical composition of claim 4~~10~~, wherein the filler is mannitol.

7~~12~~. A kit for treating a disease in a patient, the kit comprising:

(a) a pharmaceutical composition of claim 4~~comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof in the oral solid molded fast dispersing tablet~~;

(b) instructions for administering the pharmaceutical composition~~; wherein the therapeutically effective amount provides an AUC_{0-t} of from about 80-125% of 740000 (hr*pg/mL)~~.